New pyrazolopyrimidine derivatives as nik inhibitors

A method of treating or preventing a cell proliferative disease in a warm-blooded animal which comprises administering to the said animal an effective amount of a compound of Formula (I):

• or a tautomer or a stereoisomeric form thereof, wherein
• R1 is selected from the group of hydrogen;
• C1-4alkyl;
• and C1-4alkyl substituted with one or more fluoro substituents;
• R2 is selected from the group of hydrogen;
• C1-4alkyl;
• C1-4alkyl substituted with one or more fluoro substituents;
• C3-6cycloalkyl;
• and Het1;
• or R1 and R2 together with the carbon atom to which they are attached form a C3-6cycloalkyl;
• Het1 is a heteroaryl selected from the group of thienyl, thiazolyl, pyrrolyl, oxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, pyridinyl and pyrimidinyl, each of which may be optionally substituted with one or two substituents independently selected from halogen, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkyl substituted with one or more fluoro substituents, and C1-4alkyloxy substituted with one or more fluoro substituents;
• X is N or CR9;
• R9 is selected from hydrogen and halogen;
• R3 is selected from the group of hydrogen;
• halogen;
• cyano;
• C3-6cycloalkyl;
• C1-6alkyl;
• Het4;
• C1-6alkyl substituted with one or more fluoro substituents;
• —OC1-6alkyl;
• —OC1-6alkyl substituted with one or more fluoro substituents;
• and C1-6alkyl substituted with one substituent selected from —NR3aR3b and —OC1-4alkyl;
• Het4 is a heteroaryl selected from the group of piperidinyl, tetrahydropyranyl, pyrrolidinyl, tetrahydrofuranyl, azetidinyl, piperazinyl, morpholinyl and oxetanyl, each of which may be optionally substituted with one or two substituents independently selected from fluoro, C1-4alkyl, —OC1-4alkyl, C3-6cycloalkyl and C1-4alkyl substituted with one or more fluoro substituents;
• R3a and R3b are each independently selected from hydrogen and C1-4alkyl;
• R4 is hydrogen;
• R5 is selected from the group of hydrogen;
• cyano;
• C1-4alkyl;
• C1-4alkyl substituted with one or more fluoro substituents;
• C1-4alkyl substituted with one substituent selected from the group of —NR5aR5b, —OC1-4alkyl, and Het5;
• R5a and R5b are each independently selected from the group of hydrogen and C1-4alkyl;
• Het5 is a heterocyclyl selected from the group of piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, pyrrolidinyl, tetrahydrofuranyl, azetidinyl and oxetanyl, each of which may be optionally substituted with one or two substituents independently selected from fluoro, C1-4alkyl, —OC1-4alkyl, C3-6cycloalkyl and C1-4alkyl substituted with one or more fluoro substituents;
• R6 is selected from the group of hydrogen;
• Het2;
• R8;
• C1-6alkyl optionally substituted with one Het3;
• and C2-6alkyl substituted with one or more substituents independently selected from the group of fluoro, —NR6aR6b, and —OR6c;
• R6a, R6b and R6c are each independently selected from hydrogen and C1-6alkyl;
• Het2 is a heterocyclyl, bound through any available carbon atom, selected from the group of piperidinyl, tetrahydropyranyl, pyrrolidinyl, tetrahydrofuranyl, azetidinyl and oxetanyl, each of which may be optionally substituted with one or two substituents independently selected from fluoro, C1-4alkyl, —OC1-4alkyl, C3-6cycloalkyl, C1-4alkyl substituted with one —OC1-4alkyl, C1-4alkyl substituted with one C3-6cycloalkyl,
• and C1-4alkyl substituted with one or more fluoro substituents;
• Het3 is a heterocyclyl selected from the group of morpholinyl, piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidinyl, tetrahydrofuranyl, azetidinyl and oxetanyl, each of which may be optionally substituted with one or two substituents independently selected from fluoro, C3-6cycloalkyl,
• C1-4alkyl substituted with one —OC1-4alkyl,
• C1-4alkyl substituted with one C3-6cycloalkyl,
• and C1-4alkyl substituted with one or more fluoro substituents;
• R8 is C3-6cycloalkyl optionally substituted with one or two substituents independently selected from fluoro, C1-4alkyl, —OC1-4alkyl, C1-4alkyl substituted with one —OC1-4alkyl, and C1-4alkyl substituted with one or more fluoro substituents;
• R7 is selected from the group of hydrogen, C1-6alkyl, C3-6cycloalkyl and
• C1-4alkyl substituted with one —OC1-4alkyl;
• or a pharmaceutically acceptable addition salt, or a solvate thereof.